Insulin will be available also in doses that can be inhaled, instead of injecting them. In the United States, has been released a new type of insulin which can used be with the help of an inhaling device.
The medication called Afrezza, is the only type of insulin that can be inhaled, on the United States pharmaceutical market.
The use of inhalable insulin, promises a more rapid effect and has plenty more benefits than the injectable version. Although past inhalable medication haven’t always proved to be efficient, and medical experts have warned about the possible risks linked to the use of inhalable insulin.
Afrezza, is based on a whistle shaped inhalation device and can control the blood sugar levels both in the case of type 1 diabetes and type 2 diabetes. The medication, rivals Exubera, which has been developed by Pfizer and reapproved by the Food and Drug Administration in June 2014. Initially, Exubera was approved in 2006, and experts were expecting annual sales of up to $2 billion, but the inhaler proved to be to large for a comfortable use. Another reason which discouraged patients to use it, has been the fact that they were obliged to get periodical blood and pulmonary tests. Eventually Exubera, was retired from the market in 2007.
Afrezza has settled the contract last year, which stated that Mannkind Company, its producer, would receive an initial amount of $150 million and were expecting gains of $775 million plus 35% of the future gains.
Afrezza will retail for more money than Apidra, its injecatble equivalent, produced by Sanofi group. The medication sales for $ 7.54 per a daily dose of 12 units.
Patients suffering from asthma and it is not recommended for smokers or to persons who have quit smoking recently.
Financial experts of the pharmaceutical world, are expecting the inhaler to generate modest incomes, around $182 million per every year until 2019, taking account of the past problems generated by its predecessor Exubera and from the restrictions and warnings about the use of inhalable insulin.
For the future, medical researchers might come up with another option of insulin treatment. The Danish pharmaceutical group, Novo Nordisk, has successfully ended at the end of last year, the first phase of a study, which aimed to developing insulin that can be administrated orally. Insulin with this type of administration, is very difficult to create as the main protein in it, depreciates when reaching inside the stomach.
Image Source: A Sweet Life